Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of KL280006 injection for moderate to severe pruritus in maintenance hemodialysis patients
CTR20222274Phase 2Active
- Sponsor
- Sichuan Kelun-Biotech Biopharmaceutical
- Start
- Apr 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of KL280006 in chronic kidney disease-associated pruritus (CKD-aP), sponsored by Sichuan Kelun-Biotech Biopharmaceutical. Started Apr 2023; status: active.
02
Drugs
KL280006
03
Conditions
chronic kidney disease-associated pruritus (CKD-aP)
Beyond the preview
Go deeper on CTR20222274.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20222274.